Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teladoc (TDOC – Research Report), Enanta Pharmaceuticals (ENTA – Research Report) and BioMarin Pharmaceutical (BMRN – Research Report).
Teladoc (TDOC)
Truist Financial analyst Jailendra Singh maintained a Hold rating on Teladoc on October 20 and set a price target of $28.00. The company’s shares closed last Tuesday at $18.12, close to its 52-week low of $17.78.
According to TipRanks.com, Singh is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Teladoc with a $26.00 average price target, representing a 43.0% upside. In a report issued on October 5, TD Cowen also maintained a Hold rating on the stock with a $25.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Enanta Pharmaceuticals (ENTA)
In a report issued on October 20, Roanna Ruiz from Leerink Partners maintained a Hold rating on Enanta Pharmaceuticals, with a price target of $14.00. The company’s shares closed last Tuesday at $8.98, close to its 52-week low of $8.95.
According to TipRanks.com, Ruiz has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Enanta Pharmaceuticals with a $24.75 average price target.
BioMarin Pharmaceutical (BMRN)
In a report issued on October 20, Joseph Schwartz from Leerink Partners reiterated a Buy rating on BioMarin Pharmaceutical. The company’s shares closed last Tuesday at $83.35, close to its 52-week low of $80.53.
According to TipRanks.com, Schwartz is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioMarin Pharmaceutical with a $115.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TDOC:
